Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EXO-EYE

Financiado

Cerrado

Stem Cell Derived Exosomes for the treatment of Traumatic and Degenerative Eye D...

Stem Cell Derived Exosomes for the treatment of Traumatic and Degenerative Eye Disease The death and dysfunction of retinal ganglion cells (RGC) is a major cause of blindness in traumatic and degenerative ocular disease. For example, 60M people are affected by glaucoma with 4.5M becoming blind in both eyes, whilst o... ver más

31/05/2020

UoB

270K€

Presupuesto del proyecto: 270K€

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-31

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UoB

269.86K€ | Lider

United States Department of...

HHS

172.13K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STEMRD Generation of stem cell derived photoreceptors for the treat... 2M€ Cerrado

PID2020-114080GB-I00 INVESTIGANDO MECANISMOS PARA LA REGENERACION DE LA RETINA DE... 278K€ Cerrado

PID2020-115121GB-I00 CRIBADO FARMACOLOGICO IN VIVO PARA IDENTIFICAR NUEVAS VIAS D... 112K€ Cerrado

SAF2010-21317 ESTRATEGIAS DE RESCATE Y REGENERACION PARA EL TRATAMIENTO DE... 55K€ Cerrado

PCI2018-093062 NANO-ANDAMIAJE PARA LA MIGRACION Y REGENERACION NEURONAL 95K€ Cerrado

BFU2008-01060 TERAPIA NEUROTROFICA ANTIPARKINSONIANA CON CELULAS CROMAFINE... 109K€ Cerrado

Duración del proyecto: 38 meses Fecha Inicio: 2017-03-17
Fecha Fin: 2020-05-31

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 270K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The death and dysfunction of retinal ganglion cells (RGC) is a major cause of blindness in traumatic and degenerative ocular disease. For example, 60M people are affected by glaucoma with 4.5M becoming blind in both eyes, whilst optic neuritis affects 5/100,000 people and represents a significant problem for sufferers. RGC are the sole projection neurons and their axons make up the optic nerve, making them exquisitely sensitive to injury. As CNS neurons are irreplaceable, neuroprotective strategies are paramount to therapies aimed at preserving vision but as of yet, no such therapy exists. Current research has demonstrated significant neuroprotection by mesenchymal stem cells (MSC) including those from the bone marrow (BMSC), acting not as replacements for RGC but rather, as paracrine-mediated support cells. Clinical trials are already ongoing to test their efficacy in patients. Despite this, the exact mechanism behind their neuroprotective potential is not well understood. Recent studies have shown that exosomes, extracellular vesicles containing proteins, mRNA and miRNA may mediate much of the paracrine support offered by MSC and thus act as an easily purifiable cell-free alternative therapy for RGC neuroprotection. This proposal aims to assess the therapeutic efficacy of BMSC-derived exosomes, their characterisation and that of their RNA cargo. We will test these exosomes in animal models of traumatic (optic nerve crush) and degenerative (glaucoma) eye disease. Specifically, this proposal employs a novel strategy to promote RGC survival (relevant to ONC and glaucoma) and axon regeneration (relevant to optic nerve crush) through the use of exosomal delivery of mRNA/miRNA into injured RGC utilizing in vitro and in vivo injury models, RNAseq and CRISPR technology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores